Antengene

Antengene

China - Shanghai
Biotechnology
WebsiteLinkedInCareers Page

Focus: Small Molecules, Monoclonal Antibodies, Bispecifics

Antengene is a life sciences company focused on Small Molecules, Monoclonal Antibodies, Bispecifics.

Oncology
Funding Stage
PUBLIC
Employees
51-200
Open Jobs
0

Pipeline & Clinical Trials

Phase 1
Phase 1
Clinical Trials (1)
NCT06028373A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas
Phase 1
Phase 1
Clinical Trials (1)
NCT05338346A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies
Phase 1
Phase 1
Clinical Trials (1)
NCT04986865A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
Phase 1
Phase 1
Clinical Trials (1)
NCT05490043A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
Phase 1
Phase 1
Clinical Trials (1)
NCT04281420A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1
Phase 1
Clinical Trials (1)
NCT05718895A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
Phase 1
Phase 1
Phase 1
Clinical Trials (1)
NCT05354362A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase 1
Phase 1/2
Clinical Trials (1)
NCT05265975A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT05010525A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT05698147Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
Phase 1/2
Phase 1/2
ICE [ifosfamide+carboplatin+etoposide]
Peripheral T-cell Lymphoma
Phase 1/2
Clinical Trials (1)
NCT04425070A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT04691141A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS)
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT05577364Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT05422027Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma
Phase 1/2
Phase 2
Clinical Trials (1)
NCT03944057A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
Phase 2
Phase 2
Clinical Trials (1)
NCT05422066Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma
Phase 2
Phase 2
Clinical Trials (1)
NCT03591965Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects
Phase 2
ATG-010 60 mg, orally, twice weekly, each 4 week
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2
Clinical Trials (1)
NCT03992339A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 2
ATG-008 30 mg, orally, QD, each 4 week
Advanced Solid Tumors
Phase 2
Clinical Trials (1)
NCT04518137A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH)
Phase 2
Phase 3
Clinical Trials (1)
NCT05726110Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Phase 3
Phase 3
Clinical Trials (1)
NCT04939142A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 2024
Portfolio: 21 clinical trials
Publications: 9 in PubMed